MovDisordV3, Main, Exploration, bibRecord, 003438

Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation

Identifieur interne : 003438 ( Main/Exploration ); précédent : 003437; suivant : 003439

Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation

Auteurs : Rodrigo Mercado [Canada] ; Constantine Constantoyannis [Canada] ; Tomasz Mandat [Canada] ; Ajit Kumar [Canada] ; Michael Schulzer [Canada] ; A. Jon Stoessl [Canada] ; Christopher R. Honey [Canada]

Source :

Movement Disorders [ 0885-3185 ] ; 2006-09.

RBID : ISTEX:77875AEC8040A0C1B423F9C7E2142361503A27E9

Descripteurs français

Pascal (Inist)
- Attente, Effet placebo, Homme, Noyau sousthalamique, Parkinson maladie, Placebo, Stimulation cérébrale profonde, Système nerveux pathologie.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adult, Aged, Antiparkinson Agents (administration & dosage), Awareness, Combined Modality Therapy, Deep Brain Stimulation (psychology), Deep brain stimulation, Dominance, Cerebral (physiology), Dopamine Agonists (administration & dosage), Double-Blind Method, Expectation, Female, Human, Humans, Hypokinesia (physiopathology), Hypokinesia (psychology), Hypokinesia (rehabilitation), Levodopa (administration & dosage), Male, Middle Aged, Nervous system diseases, Neurologic Examination, Parkinson Disease (physiopathology), Parkinson Disease (psychology), Parkinson Disease (rehabilitation), Parkinson disease, Parkinson's disease, Placebo, Placebo Effect, Placebo effect, Set (Psychology), Subthalamic Nucleus (physiopathology), Subthalamic nucleus, deep brain stimulation, nocebo, placebo, subthalamic nucleus.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Dopamine Agonists, Levodopa.
- physiology : Dominance, Cerebral.
- physiopathology : Hypokinesia, Parkinson Disease, Subthalamic Nucleus.
- psychology : Deep Brain Stimulation, Hypokinesia, Parkinson Disease.
- rehabilitation : Hypokinesia, Parkinson Disease.
- Adult, Aged, Awareness, Combined Modality Therapy, Double-Blind Method, Female, Humans, Male, Middle Aged, Neurologic Examination, Placebo Effect, Set (Psychology).

Abstract

To determine whether the degree to which a patient with Parkinson's disease expects therapeutic benefit from subthalamic nucleus–deep brain stimulation (STN‐DBS) influences the magnitude of his or her improved motor response, 10 patients with idiopathic Parkinson's and bilateral STN‐DBS were tested after a 12‐hour period off medication and stimulation. Four consecutive UPDRS III scores were performed in the following conditions: (a) stimulation OFF, patient aware; (b) stimulation OFF, patient blind; (c) stimulation ON, patient aware; and (d) stimulation ON, patient blind. Statistical significance (P = 0.0001) was observed when comparing main effect ON versus OFF (mean ON: 32.55; mean OFF: 49.15). When the stimulation was OFF, patients aware of this condition had higher UPDRS motor scores than when they were blinded (mean: 50.7 vs. 47.6). With the stimulation ON, UPDRS motor scores were lower when the patients were aware of the stimulation compared with when they were blinded (mean: 30.6 vs. 34.5). The interaction between these levels was significant (P = 0.049). This variation was important for bradykinesia and was not significant for tremor and rigidity. The authors conclude that the information about the condition of the stimulation enhanced the final clinical effect in opposite directions. The results presented support the role of expectation and placebo effects in STN‐DBS in Parkinson's disease patients. © 2006 Movement Disorder Society

Url:

https://api.istex.fr/document/77875AEC8040A0C1B423F9C7E2142361503A27E9/fulltext/pdf

DOI: 10.1002/mds.20935

Affiliations:

Canada

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation</title>
<author><name sortKey="Mercado, Rodrigo" sort="Mercado, Rodrigo" uniqKey="Mercado R" first="Rodrigo" last="Mercado">Rodrigo Mercado</name>
</author>
<author><name sortKey="Constantoyannis, Constantine" sort="Constantoyannis, Constantine" uniqKey="Constantoyannis C" first="Constantine" last="Constantoyannis">Constantine Constantoyannis</name>
</author>
<author><name sortKey="Mandat, Tomasz" sort="Mandat, Tomasz" uniqKey="Mandat T" first="Tomasz" last="Mandat">Tomasz Mandat</name>
</author>
<author><name sortKey="Kumar, Ajit" sort="Kumar, Ajit" uniqKey="Kumar A" first="Ajit" last="Kumar">Ajit Kumar</name>
</author>
<author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
</author>
<author><name sortKey="Honey, Christopher R" sort="Honey, Christopher R" uniqKey="Honey C" first="Christopher R." last="Honey">Christopher R. Honey</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:77875AEC8040A0C1B423F9C7E2142361503A27E9</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20935</idno>
<idno type="url">https://api.istex.fr/document/77875AEC8040A0C1B423F9C7E2142361503A27E9/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001694</idno>
<idno type="wicri:Area/Istex/Curation">001694</idno>
<idno type="wicri:Area/Istex/Checkpoint">001E98</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Mercado R:expectation:and:the</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16721750</idno>
<idno type="wicri:Area/PubMed/Corpus">002C23</idno>
<idno type="wicri:Area/PubMed/Curation">002C23</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002D29</idno>
<idno type="wicri:Area/Ncbi/Merge">001711</idno>
<idno type="wicri:Area/Ncbi/Curation">001711</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001711</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Mercado R:expectation:and:the</idno>
<idno type="wicri:Area/Main/Merge">004752</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0518102</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001994</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001327</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001B00</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Mercado R:expectation:and:the</idno>
<idno type="wicri:Area/Main/Merge">004B95</idno>
<idno type="wicri:Area/Main/Curation">003438</idno>
<idno type="wicri:Area/Main/Exploration">003438</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation</title>
<author><name sortKey="Mercado, Rodrigo" sort="Mercado, Rodrigo" uniqKey="Mercado R" first="Rodrigo" last="Mercado">Rodrigo Mercado</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Surgical Centre for Movement Disorders, University of British Columbia, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Constantoyannis, Constantine" sort="Constantoyannis, Constantine" uniqKey="Constantoyannis C" first="Constantine" last="Constantoyannis">Constantine Constantoyannis</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Surgical Centre for Movement Disorders, University of British Columbia, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mandat, Tomasz" sort="Mandat, Tomasz" uniqKey="Mandat T" first="Tomasz" last="Mandat">Tomasz Mandat</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Surgical Centre for Movement Disorders, University of British Columbia, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kumar, Ajit" sort="Kumar, Ajit" uniqKey="Kumar A" first="Ajit" last="Kumar">Ajit Kumar</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Pacific Parkinson's Disease Research Center, University of British Columbia, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Pacific Parkinson's Disease Research Center, University of British Columbia, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Pacific Parkinson's Disease Research Center, University of British Columbia, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Honey, Christopher R" sort="Honey, Christopher R" uniqKey="Honey C" first="Christopher R." last="Honey">Christopher R. Honey</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Surgical Centre for Movement Disorders, University of British Columbia, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-09">2006-09</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1457">1457</biblScope>
<biblScope unit="page" to="1461">1461</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">77875AEC8040A0C1B423F9C7E2142361503A27E9</idno>
<idno type="DOI">10.1002/mds.20935</idno>
<idno type="ArticleID">MDS20935</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Awareness</term>
<term>Combined Modality Therapy</term>
<term>Deep Brain Stimulation (psychology)</term>
<term>Deep brain stimulation</term>
<term>Dominance, Cerebral (physiology)</term>
<term>Dopamine Agonists (administration & dosage)</term>
<term>Double-Blind Method</term>
<term>Expectation</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Hypokinesia (physiopathology)</term>
<term>Hypokinesia (psychology)</term>
<term>Hypokinesia (rehabilitation)</term>
<term>Levodopa (administration & dosage)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Neurologic Examination</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson Disease (rehabilitation)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Placebo</term>
<term>Placebo Effect</term>
<term>Placebo effect</term>
<term>Set (Psychology)</term>
<term>Subthalamic Nucleus (physiopathology)</term>
<term>Subthalamic nucleus</term>
<term>deep brain stimulation</term>
<term>nocebo</term>
<term>placebo</term>
<term>subthalamic nucleus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Dominance, Cerebral</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hypokinesia</term>
<term>Parkinson Disease</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Deep Brain Stimulation</term>
<term>Hypokinesia</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="rehabilitation" xml:lang="en"><term>Hypokinesia</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Awareness</term>
<term>Combined Modality Therapy</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurologic Examination</term>
<term>Placebo Effect</term>
<term>Set (Psychology)</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Attente</term>
<term>Effet placebo</term>
<term>Homme</term>
<term>Noyau sousthalamique</term>
<term>Parkinson maladie</term>
<term>Placebo</term>
<term>Stimulation cérébrale profonde</term>
<term>Système nerveux pathologie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To determine whether the degree to which a patient with Parkinson's disease expects therapeutic benefit from subthalamic nucleus–deep brain stimulation (STN‐DBS) influences the magnitude of his or her improved motor response, 10 patients with idiopathic Parkinson's and bilateral STN‐DBS were tested after a 12‐hour period off medication and stimulation. Four consecutive UPDRS III scores were performed in the following conditions: (a) stimulation OFF, patient aware; (b) stimulation OFF, patient blind; (c) stimulation ON, patient aware; and (d) stimulation ON, patient blind. Statistical significance (P = 0.0001) was observed when comparing main effect ON versus OFF (mean ON: 32.55; mean OFF: 49.15). When the stimulation was OFF, patients aware of this condition had higher UPDRS motor scores than when they were blinded (mean: 50.7 vs. 47.6). With the stimulation ON, UPDRS motor scores were lower when the patients were aware of the stimulation compared with when they were blinded (mean: 30.6 vs. 34.5). The interaction between these levels was significant (P = 0.049). This variation was important for bradykinesia and was not significant for tremor and rigidity. The authors conclude that the information about the condition of the stimulation enhanced the final clinical effect in opposite directions. The results presented support the role of expectation and placebo effects in STN‐DBS in Parkinson's disease patients. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Mercado, Rodrigo" sort="Mercado, Rodrigo" uniqKey="Mercado R" first="Rodrigo" last="Mercado">Rodrigo Mercado</name>
</noRegion>
<name sortKey="Constantoyannis, Constantine" sort="Constantoyannis, Constantine" uniqKey="Constantoyannis C" first="Constantine" last="Constantoyannis">Constantine Constantoyannis</name>
<name sortKey="Honey, Christopher R" sort="Honey, Christopher R" uniqKey="Honey C" first="Christopher R." last="Honey">Christopher R. Honey</name>
<name sortKey="Kumar, Ajit" sort="Kumar, Ajit" uniqKey="Kumar A" first="Ajit" last="Kumar">Ajit Kumar</name>
<name sortKey="Mandat, Tomasz" sort="Mandat, Tomasz" uniqKey="Mandat T" first="Tomasz" last="Mandat">Tomasz Mandat</name>
<name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003438 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003438 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:77875AEC8040A0C1B423F9C7E2142361503A27E9
   |texte=   Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation

Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.